Benjamin Levy, MD

Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Expert perspectives on selecting between neoadjuvant and perioperative chemoimmunotherapy in patients with resectable early-stage NSCLC.

Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.

The panel reflects on challenges with the EMR, and the impact it has on treatment decision making for their patients with NSCLC.

Bhuvana Ramkumar, MD, highlights the strengths of liquid biopsy for molecular testing in NSCLC.

Experts discuss the types of genotype panels they often use for testing patients with NSCLC, and why.

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.

Drs Fernando C. Santini and Hatim Hussain explain how they approach testing and treatment of patients with TRK fusion at diagnosis and progression in non–small cell lung cancer.

A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.

Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.

Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.